Protagonist Therapeutics, Inc. (PTGX) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Protagonist Therapeutics, Inc. (PTGX) Bundle
Engineered for accuracy, our (PTGX) DCF Calculator empowers you to evaluate Protagonist Therapeutics, Inc. valuation using real-world financial data and offers complete flexibility to modify all essential parameters for enhanced predictions.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .2 | 28.6 | 27.4 | 26.6 | 60.0 | 88.9 | 131.7 | 195.2 | 289.3 | 428.7 |
| Revenue Growth, % | 0 | 12293.07 | -4.44 | -2.84 | 125.73 | 48.18 | 48.18 | 48.18 | 48.18 | 48.18 |
| EBITDA | -78.3 | -63.7 | -123.1 | -131.4 | -90.3 | -88.9 | -131.7 | -195.2 | -289.3 | -428.7 |
| EBITDA, % | -33898.7 | -222.38 | -449.87 | -494.24 | -150.57 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .7 | .8 | 2.8 | 1.0 | 3.3 | 21.7 | 32.2 | 47.8 | 70.8 | 104.9 |
| Depreciation, % | 304.33 | 2.76 | 10.14 | 3.88 | 5.52 | 24.46 | 24.46 | 24.46 | 24.46 | 24.46 |
| EBIT | -79.0 | -64.5 | -125.8 | -132.4 | -93.7 | -88.9 | -131.7 | -195.2 | -289.3 | -428.7 |
| EBIT, % | -34203.03 | -225.13 | -460.01 | -498.12 | -156.09 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 133.0 | 307.8 | 326.9 | 237.4 | 341.6 | 88.9 | 131.7 | 195.2 | 289.3 | 428.7 |
| Total Cash, percent | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 6.8 | 2.4 | 1.6 | .1 | 10.3 | 23.4 | 34.7 | 51.4 | 76.1 | 112.8 |
| Account Receivables, % | 2924.24 | 8.47 | 5.72 | 0.19563 | 17.22 | 26.32 | 26.32 | 26.32 | 26.32 | 26.32 |
| Inventories | 4.8 | 4.0 | 8.5 | -.1 | .0 | 25.7 | 38.1 | 56.5 | 83.7 | 124.0 |
| Inventories, % | 2075.76 | 13.89 | 31.08 | -0.35364 | 0 | 28.92 | 28.92 | 28.92 | 28.92 | 28.92 |
| Accounts Payable | 2.8 | 3.1 | 1.6 | 3.6 | .8 | 23.4 | 34.7 | 51.4 | 76.1 | 112.8 |
| Accounts Payable, % | 1207.79 | 10.74 | 5.85 | 13.69 | 1.29 | 26.31 | 26.31 | 26.31 | 26.31 | 26.31 |
| Capital Expenditure | -1.0 | -.5 | -1.1 | -.8 | -.6 | -19.5 | -28.9 | -42.8 | -63.5 | -94.0 |
| Capital Expenditure, % | -418.61 | -1.65 | -4.02 | -2.99 | -1.02 | -21.94 | -21.94 | -21.94 | -21.94 | -21.94 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -78.3 | -65.7 | -122.9 | -128.3 | -93.7 | -87.8 | -130.1 | -192.7 | -285.6 | -423.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -87.3 | -60.0 | -126.4 | -115.9 | -104.2 | -101.7 | -139.1 | -206.2 | -305.5 | -452.7 |
| WACC, % | 14.65 | 14.65 | 14.65 | 14.65 | 14.65 | 14.65 | 14.65 | 14.65 | 14.65 | 14.65 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -736.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -462 | |||||||||
| Terminal Value | -3,649 | |||||||||
| Present Terminal Value | -1,842 | |||||||||
| Enterprise Value | -2,579 | |||||||||
| Net Debt | -186 | |||||||||
| Equity Value | -2,393 | |||||||||
| Diluted Shares Outstanding, MM | 57 | |||||||||
| Equity Value Per Share | -42.16 |
What You Will Get
- Editable Forecast Inputs: Easily adjust key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Protagonist Therapeutics, Inc. (PTGX) financial data pre-loaded to facilitate your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Customizable and Professional: A refined Excel model tailored to meet your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and optimizing efficiency.
Key Features
- Customizable Research Parameters: Adjust vital inputs such as clinical trial success rates, market penetration, and revenue forecasts.
- Instant Valuation Calculations: Quickly derives intrinsic value, NPV, and other key financial metrics.
- High-Precision Analytics: Leverages Protagonist’s real-world data for accurate valuation results.
- Streamlined Scenario Analysis: Effortlessly evaluate various assumptions and analyze different outcomes.
- Efficiency Booster: Avoid the complexities of developing detailed valuation models from the ground up.
How It Works
- Download the Template: Gain immediate access to the Excel-based PTGX DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and more.
- Instant Calculations: The model automatically adjusts Protagonist Therapeutics’ intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential valuation shifts.
- Analyze and Decide: Utilize the results to inform your investment or financial analysis.
Why Choose Protagonist Therapeutics, Inc. (PTGX)?
- Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
- Scientific Expertise: Backed by a team of industry-leading researchers and professionals.
- Robust Pipeline: A diverse range of drug candidates in various stages of development.
- Commitment to Patients: Focused on delivering transformative treatments for patients.
- Proven Track Record: Established credibility in the biotechnology sector.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Protagonist Therapeutics stock (PTGX).
- Financial Analysts: Enhance valuation processes with ready-to-use financial models specific to Protagonist Therapeutics (PTGX).
- Consultants: Provide professional valuation insights on Protagonist Therapeutics (PTGX) to clients quickly and accurately.
- Business Owners: Gain insights into how biotech companies like Protagonist Therapeutics (PTGX) are valued to inform your own strategy.
- Finance Students: Explore valuation techniques using real-world data and scenarios related to Protagonist Therapeutics (PTGX).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Protagonist Therapeutics, Inc. (PTGX) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Protagonist Therapeutics, Inc. (PTGX).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.